Novartis’ decision to withdraw a European filing for its dry-eye drug Xiidra is to have a knock-on effect on Takeda, causing it to make a loss of $200 million this quarter.
There isn’t enough evidence to back the use of Novartis Mayzent for secondary progressive multiple sclerosis on the NHS (SPMS), despite a desperate lack of treatments for this
Canadian start-up AccessNow has won first prize in a Novartis competition to find technological ways to help people with multiple sclerosis lead independent lives.
Novartis and eyecare spinout Alcon have agreed to settle bribery charges brought by the US federal authorities, focused on activities in Greece and other countries, for $347 mi
Novartis is set to launch its one-off gene therapy Zolgensma for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA) in Germany at the start of July priced at 1,945,000 euro
Bristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies by market cap into the top 10, according to a new analysis by GlobalDat